Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women with overweight or obesity, researchers reported at ENDO 2025. “We found an ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...